Personalized therapy for a single patient with CHCHD10 ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial is designed for one specific patient with a rare genetic form of ALS caused by a mutation in the CHCHD10 gene. It tests an experimental therapy made just for that person's genetic mutation, aiming to slow or stop the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic brain or nerve disorder, specifically caused by a CHCHD10 mutation.
- You must be able to travel to the study location for all visits and follow-ups.
- You (or a family member or guardian) must give permission to be in the study.
- You cannot be taking any other experimental drug within 5 half-lives before starting this treatment.
- You must not have any other condition that would interfere with completing the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized medicine approach for people with a specific genetic form of ALS caused by changes in the CHCHD10 gene. A custom-designed antisense oligonucleotide (a type of genetic therapy) is used to target the underlying cause of the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.